irofulven has been researched along with Ovarian Neoplasms in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (85.71) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Blessing, JA; McMeekin, S; Miller, DS; Muller, CY; Rotmensch, J; Schilder, RJ; Shahin, MS; Tewari, KS; Warshal, DP | 1 |
| Cvitkovic, E; Koeppel, F; Larsen, AK; Poindessous, V; Raymond, E; Waters, SJ | 1 |
| Burks, J; Cunningham, C; Mikell, C; Reed, E; Van Laar, ES; Wang, J; Wang, W; Wang, Y; Waters, SJ; Wiltshire, T | 1 |
| Calvo, F; Cvitkovic, E; Koeppel, F; Laar, ES; Larsen, AK; Lokiec, F; Poindessous, V; Raymond, E; Serova, M; Waters, SJ | 1 |
| Alberts, DS; Bodurka, DC; Cullen, M; Gordon, AN; Matulonis, UA; McGuire, WP; Penson, RT; Reed, E; Seiden, MV; Weems, G | 1 |
| Reed, E; Senft, J; Wang, W; Wang, Y; Wenger, SL; Wiltshire, T | 1 |
| Dings, RP; Griffin, RJ; MacDonald, JR; Mayo, KH; Van Laar, ES; Waters, SJ; Webber, J; Zhang, Y | 1 |
2 trial(s) available for irofulven and Ovarian Neoplasms
| Article | Year |
|---|---|
A phase 2 evaluation of irofulven as second-line treatment of recurrent or persistent intermediately platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Salvage Therapy; Sesquiterpenes; Survival Rate; Treatment Outcome | 2010 |
A phase II study of irofulven in women with recurrent and heavily pretreated ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Cohort Studies; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Sesquiterpenes | 2006 |
5 other study(ies) available for irofulven and Ovarian Neoplasms
| Article | Year |
|---|---|
Enhanced antitumor activity of irofulven in combination with 5-fluorouracil and cisplatin in human colon and ovarian carcinoma cells.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cell Line, Tumor; Cisplatin; Coloring Agents; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Inhibitory Concentration 50; Models, Chemical; Ovarian Neoplasms; Sesquiterpenes; Tetrazolium Salts; Thiazoles | 2003 |
ATM-dependent CHK2 activation induced by anticancer agent, irofulven.
Topics: Antineoplastic Agents, Alkylating; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; Cell Line, Tumor; Checkpoint Kinase 1; Checkpoint Kinase 2; Chromosomal Proteins, Non-Histone; DNA-Binding Proteins; Female; Humans; Nuclear Proteins; Ovarian Neoplasms; Phosphorylation; Protein Kinases; Protein Serine-Threonine Kinases; S Phase; Serine; Sesquiterpenes; Signal Transduction; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2004 |
Characterizations of irofulven cytotoxicity in combination with cisplatin and oxaliplatin in human colon, breast, and ovarian cancer cells.
Topics: Algorithms; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cisplatin; Colonic Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Female; Genes, p53; HT29 Cells; Humans; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Sesquiterpenes; Tetrazolium Salts; Thiazoles | 2006 |
Fanconi anemia D2 protein confers chemoresistance in response to the anticancer agent, irofulven.
Topics: Antineoplastic Agents, Alkylating; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; Cell Line, Tumor; Chromosomes, Human; DNA Damage; Drug Resistance, Neoplasm; Fanconi Anemia Complementation Group D2 Protein; Female; Genes, BRCA1; Genes, BRCA2; Humans; Ovarian Neoplasms; Protein Serine-Threonine Kinases; Sesquiterpenes; Transfection; Ubiquitins | 2006 |
Ovarian tumor growth regression using a combination of vascular targeting agents anginex or topomimetic 0118 and the chemotherapeutic irofulven.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Calixarenes; Cell Line, Tumor; Cell Proliferation; Female; Humans; Mice; Ovarian Neoplasms; Peptides; Proteins; Sesquiterpenes; Xenograft Model Antitumor Assays | 2008 |